Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Upcoming Drifts in Bio-similars

Author(s): Geeta Aggarwal, Manju Nagpal*, Ameya Sharma, Vivek Puri and Gitika Arora Dhingra

Volume 16, Issue 1, 2021

Published on: 07 May, 2020

Page: [39 - 51] Pages: 13

DOI: 10.2174/1574884715666200507131943

Price: $65

Abstract

Background: Biopharmaceuticals such as biological, medicinal products have been in clinical use over the past three decades and have benefited the therapy of degenerative and critical metabolic diseases. It is forecasted that the market of biologics will be going to increase at a rate of ˃ 20% per year, and by 2025, more than 50% of new drug approvals might be biological products. The increasing utilization of the biologics necessitates cost control, especially for innovator products that have a lengthy period of exclusive usage. As the first wave of biopharmaceuticals is expired or set to expire, it has led to various opportunities for the expansion of bio-similars i.e. copied versions of original biologics with same the biological activity. Development of biosimilars is expected to promote market competition, meet worldwide demand, sustain the healthcare systems and maintain the incentives for innovation.

Methods: Appraisal of published articles from peer-reviewed journals, PubMed literature, latest news and guidelines from European Medicine Agency, US Food Drug Administration (FDA) and India were used to identify data for review.

Results: Main insights into the quality requirements concerning biologics, the current status of regulation of bio-similars and upcoming challenges lying for the upgrading of the marketing authorization of biosimilars have been incorporated. Compiled literature on the therapeutic status, regulatory guidelines and the emerging trends and opportunities of biosimilars has been thoroughly stated.

Conclusion: Updates on biosimilars will support to investigate the possible impact of bio-similars on the healthcare market.

Keywords: Biologics, biosimilars, regulatory, EMA, FDA, global market.

« Previous Next »
Graphical Abstract

[1]
Sekhon BS. Biopharmaceuticals: An overview. Thaiphesatchasan 2010; 34(34): 1-9.
[2]
Dimitrov DS. Therapeutic antibodies, vaccines and antibodyomes. MAbs 2010; 2(3): 347-56.
[http://dx.doi.org/10.4161/mabs.2.3.11779] [PMID: 20400863]
[3]
Mukherjee R. 2016.http://timesofindia.indiatimes.com/business/india-business/Biologics-enter-top-selling-drugs-list/articleshow/56209425.cms [Accessed on 14th Jan 2020].
[4]
Stone K. https://www.thebalance.com/top-biologic-drugs-2663233 [Accessed on 14th Jan 2020]
[5]
King S. 2014.Available at:. https://www.firstwordpharma.com/node/1194000
[6]
Aitken M. 2016.Available at:. http://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Documents/IMS_Institute_Bio-similar_Brief_March_2016.pdf [Accessed on 10th Jan 2020]
[7]
Morrow T, Felcone LH. Defining the difference: What Makes Biologics Unique. Biotechnol Healthc 2004; 1(4): 24-9.
[PMID: 23393437]
[8]
Otto R, Santagostino A, Schrader U. http://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/rapid-growth-in-biopharma [Accessed on 14th Jan 2020]
[9]
Brand R. 2017.https://www.lifescienceleader.com/doc/drug-pricing-s-challenge-confronting-biopharma-0001 [Accessed on 10th Dec 2019]
[10]
Park DI. Current status of biosimilars in the treatment of inflammatory bowel diseases. Intest Res 2016; 14(1): 15-20.
[http://dx.doi.org/10.5217/ir.2016.14.1.15] [PMID: 26884730]
[11]
Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits 2013; 6(8): 469-78.
[PMID: 24991376]
[12]
Dolinar RO, Reilly MS. The future of biological therapy: A pathway forward for Bio-similars. GaBi J 2013; 2(1): 36-40.
[http://dx.doi.org/10.5639/gabij.2013.0201.014]
[13]
https://www.ema.europa.eu/en/human-regulatory/overview/bio-similar-medicines-overview [Accessed on 13th Jan 2020].
[14]
Anour R. Bio-similars vs. ‘biobetters’- A regulator’s perspective. Generics and Bio-similars Initiative Journal. GaBi J 2014; 3(4): 166-7.
[http://dx.doi.org/10.5639/gabij.2014.0304.039]
[15]
Kumar R, Singh J. Biosimilar drugs: Current status. Int J Appl Basic Med Res 2014; 4(2): 63-6.
[http://dx.doi.org/10.4103/2229-516X.136774] [PMID: 25143877]
[16]
Declerck PJ. Biologicals and bio-similars: A review of the science and its implications. GaBi J 2012; 1(1): 13-6.
[http://dx.doi.org/10.5639/gabij.2012.0101.005]
[17]
Yu B. Greater potential cost savings with biosimilar use. Am J Manag Care 2016; 22(5): 378.
[PMID: 27266439]
[18]
Aapro M. Bio-similars in oncology: Current and future perspectives. GaBi J 2013; 2(2): 91-3.
[http://dx.doi.org/10.5639/gabij.2013.0202.023]
[19]
Reinisch W, Smolen J. Biosimilar safety factors in clinical practice. Semin Arthritis Rheum 2015; 44(6)(Suppl.): S9-S15.
[http://dx.doi.org/10.1016/j.semarthrit.2015.04.005] [PMID: 26058551]
[20]
Chablani L. Pharmacovigilance of bio-similars J Pharmacovigil 2013; 1e107
[http://dx.doi.org/10.4172/2329-6887.1000e107]
[21]
Heinemann L, Khatami H, McKinnon R, Home P. An overview of current regulatory requirements for approval of biosimilar insulins. Diabetes Technol Ther 2015; 17(7): 510-26.
[http://dx.doi.org/10.1089/dia.2014.0362] [PMID: 25789689]
[22]
Oskouei ST. 2018.https://www.centerforbio-similars.com/contributor/sonia-oskouei/04/2018/bio-similar-interchangeability-9-things-to-consider [Accessed on 14th Jan 2020].
[23]
Mezher M. 2016.http://www.raps.org/Regulatory Focus/News/2016/08/15/25603/EMA-Adopts-New-Biologic-Bio-similar-Pharmacovigilance-Guidance/ [Accessed on 14th Jan 2020].
[24]
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf [Accessed on 7th May 2017]
[25]
2020.https://www.fda.gov/drugs/guidancecomplianceregulatory information/guidances/ucm290967.htm [Accessed on 5th Jan 2020]
[26]
Christl L. FDA’s Overview of the Regulatory Guidance for the Development and Approval of Bio-similar Products in the US https://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/bio-similars/ucm428732.pdf [Accessed on 7th May 2019].
[27]
Brennan Z. India releases New Bio-similars Guidance 28 th March, 2016 [Accessed on 7th Jan, 2020] Available from: http://www.raps.org/Regulatory-Focus/News/2016/03/28/24638/India-Releases-New- Bio-similars-Guidance/
[28]
Surge of Indian Bio-similars Market Forecast in 2019 16 th April,2019 [Accessed on 26th Dec, 2019] Available from https://www.bio-similardevelopment.com/doc/surge-of-indian-bio-similars-market-forecast-in-0001
[29]
Panesar K. Bio-similars: Current approvals and pipeline agents. US Pharm 2016; 41(10): 26-9.
[30]
Bio-similars product information [Accessed on 5th Jan, 2020] Available from: https://www.fda.gov/drugs/bio-similars/bio-similar-product-information
[31]
Bio-similars in Europe: Information guide for healthcare professionalsAccessed on 7th Jan, 2020] Available from: https://www.ema.europa.eu/en/documents/leaflet/bio-similars-eu-information-guide- healthcare-professionals_en.pdf
[32]
Mirasol F. Roundup of European Bio-similars approved in 2018.[Accessed on 14th Jan, 2020]. Available from:. http://www.pharmtech.com/roundup-european-bio-similars-approved-2018
[33]
Jung EH, Sarpatwari A, Kesselheim AS, Sinha MS. FDA and EMA bio-similar approvals. J Gen Intern Med 2019; 2: 1-3.
[34]
Calo-Fernández B, Martínez-Hurtado JL. Biosimilars: Company strategies to capture value from the biologics market. Pharmaceuticals (Basel) 2012; 5(12): 1393-408.
[http://dx.doi.org/10.3390/ph5121393] [PMID: 24281342]
[35]
Kamaraj R, Manju M. Bio-similar current status in India. Asian J Pharm Clin Res 2017; 10(1): 25-8.
[http://dx.doi.org/10.22159/ajpcr.2017.v10i1.14814]
[36]
Welch AR. Bio-similar Development 2016.https://www. lifescienceleader.com/doc/why-is-the-year-to-watch-bio-similars-0001 [Accessed on 7th May 2019].
[37]
Research and Market report. Bio-similar Market: Global Industry Analysis, Trends, Market Size & Forecasts to 2023. May 03, 2017. [Accessed on 7 th May], 2019. Available from:. http://www.businesswire.com/news/home/20170503006253/en/3.3-Billion-Bio-similar-Market-2017-Global-Industry
[38]
. Universal Bio-similars Market is expected to reach CAGR of 26.3% by 2021. [Accessed on 7 th May], 2019. Available from:. http://www.crossroadstoday.com/story/35351049/latest-report-says-universal-bio-similars-market-is-expected-to-reach-cagr-of-263-by-2021
[39]
Blackstone EA, and Joseph PF. The economics of bio-similars. Am Health Drug Benefits 2013; 6(8): 469-78.
[40]
Biologicals patent expires. Posted 13/11/2015. [Accessed on 9 th May, 2019]. Available from:. http://www.gabionline.net/Bio-similars/General/Biologicals-patent-expiries
[41]
Going global: India’s big bio-similar move. [Accessed on 7th May, 2019]. Available from:. http://www.pharmaceutical-technology. com/features/featuregoing-global-indias-big-bio-similar-move-5001775/
[42]
Top 4 trends impacting the global mAB bio-similars market through 2020: Technavio. October 04, 2016. [Accessed on 7th July 2019]. Available from:. http://www.businesswire.com/news/home/20161004005970/en/Top-4-Trends-Impacting-Global-mAb-Bio-similars
[43]
Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies. 3 Aug, 2015: [Accessed on 7th July 2019]. Available from:. http://www.prnewswire.com/news-releases/sorrento-in-licenses-four-late-stage-clinical-biobetter-and-bio-similar-antibodies-300122278.html
[44]
Torrent Pharma . Reliance Life sign licensing agreement for Bio-similarsBusiness Standards December 26, 2014 [Accessed on 9th May, 2019] Available from: http://www.business-standard.com/article/companies/torrent-pharma-reliance-life-sign-licensing-agreement-for-bio-similars-114122500631_1.html

Rights & Permissions Print Cite
Article Metrics
7
1
© 2024 Bentham Science Publishers | Privacy Policy